CYTOVENE - CAP 250MG 250 MG
GANCICLOVIR : 250 MG · DIN 02186802 · HOFFMANN-LA ROCHE LIMITED
Health Canada status: CANCELLED POST MARKET
What is CYTOVENE - CAP 250MG?
CYTOVENE - CAP 250MG 250 MG contains GANCICLOVIR : 250 MG. It is listed in the Health Canada Drug Product Database under DIN 02186802, held by HOFFMANN-LA ROCHE LIMITED, supplied as CAPSULE for ORAL administration. Health Canada currently lists it as cancelled post market, status dated 02-Aug-2007. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
Product details and regulatory record
| DIN | 02186802 |
|---|---|
| Brand name | CYTOVENE - CAP 250MG |
| Generic / active ingredient | GANCICLOVIR : 250 MG |
| Manufacturer | HOFFMANN-LA ROCHE LIMITED |
| Strength | 250 MG |
| Dosage form | CAPSULE |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | J05AB06 GANCICLOVIR |
| AHFS class | 08:18.32 |
| Biosimilar | No |
| Health Canada status | CANCELLED POST MARKET |
| Status date | 02-Aug-2007 |
| Original market date | 1995-12-31 00:00:00 |
What can be used instead?
Other Canadian products sharing ATC code J05AB06 GANCICLOVIR. 4 of 9 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| CYTOVENE | 500 MG | POWDER FOR SOLUTION | CHEPLAPHARM ARZNEIMITTEL GMBH | MARKETED | DIN 02162695 |
| GANCICLOVIR FOR INJECTION | 500 MG | POWDER FOR SOLUTION | FORMATIVE PHARMA INC. | MARKETED | DIN 02537168 |
| GANCICLOVIR FOR INJECTION | 500 MG | POWDER FOR SOLUTION | FRESENIUS KABI CANADA LTD | MARKETED | DIN 02404761 |
| GANCICLOVIR FOR INJECTION USP | 500 MG | POWDER FOR SOLUTION | STERIMAX INC | MARKETED | DIN 02475391 |
| CYTOVENE INJ 500MG/VIAL | 500 MG | POWDER FOR SOLUTION | SYNTEX INC. | CANCELLED POST MARKET | DIN 00865516 |
| CYTOVENE, 500 MG | 500 MG | CAPSULE | HOFFMANN-LA ROCHE LIMITED | CANCELLED POST MARKET | DIN 02240362 |
| GANCICLOVIR FOR INJECTION USP | 500 MG | POWDER FOR SOLUTION | EUGIA PHARMA INC. | APPROVED | DIN 02538911 |
| GANCICLOVIR FOR INJECTION USP | 500 MG | POWDER FOR SOLUTION | AURO PHARMA INC | APPROVED | DIN 02471930 |
Who else supplies GANCICLOVIR worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. GANCICLOVIR appears in 41 registered pack listings across 11 markets, published on 8 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.